{"filings":[{"id":92438,"accession_number":"0001683168-26-003381","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals prices $4.0M public offering of units at $1.35/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,962,962 units initially, each unit one share (or pre-funded warrant) and one warrant at $1.35 per unit.","Total gross proceeds ~$4.0M; net proceeds ~$3.5M after underwriting discount and expenses.","Closing occurred April 27-28, 2026 with full over-allotment exercise; 1,650,716 common shares, 1,312,247 pre-funded warrants, 3,407,404 warrants issued.","Warrants exercisable at $1.35 per share for five years; Underwriters' warrants for 5% of sold securities at 110% of offering price.","Net proceeds to be used for general corporate purposes including working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92437,"accession_number":"0001683168-26-002761","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals enters manufacturing supply agreement with Kenvue for Microcyn products in US","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Kenvue Brands LLC for US sale of Microcyn-based products, effective Oct 24, 2025 through March 2027.","Term includes two optional one-year renewals upon mutual written agreement.","Kenvue is not obligated to buy any minimum quantity; binding orders from 12-week forecast periods.","Most-favored-customer clause requires Sonoma to extend better pricing offered to comparable CPG customers to Kenvue.","Agreement is non-exclusive; Kenvue may manufacture or source similar products from third parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103279,"accession_number":"0001683168-26-000589","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals appoints Vanessa Jacoby to board; Birnbaum retires as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jay Birnbaum retired from board Jan 28, 2026; will serve as consultant for one year, receiving 5,000 RSUs per quarter.","Vanessa Jacoby appointed director effective Jan 28, replaces Birnbaum as independent director; will chair Audit Committee.","Jacoby receives initial grant of options to purchase 10,000 shares vesting over 3 years; annual retainer $32,500 plus committee fees.","Board amended director compensation plan to allow discretion in annual option grant size and form of initial equity grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103278,"accession_number":"0001683168-26-000205","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals files updated investor presentation; no specific financial or operational details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing includes an updated investor presentation as of January 2026, furnished as Exhibit 99.1.","The presentation content is not fully provided; only legal disclaimers are visible in the filing.","No new financial results, guidance, or material events are disclosed in the filing text.","The presentation may contain updates on commercial progress, but specifics are not available from this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103277,"accession_number":"0001683168-26-000027","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sonoma Pharmaceuticals grants annual equity to executives and directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Non-employee directors each received 10,000 options at $3.68, vesting in 3 equal annual tranches.","CEO Amy Trombly received 10,000 RSUs vesting on the third anniversary or upon change of control.","CFO Jerry Dvonch received 5,000 RSUs vesting on the third anniversary or upon change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119532,"accession_number":"0001683168-25-007750","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sonoma Pharma terminates EVP/COO Bruce Thornton for cause, effective Oct 18","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruce Thornton terminated as EVP and Chief Operating Officer on October 18, 2025.","Termination was for cause under his employment agreement; no severance or future benefits.","Thornton will only receive salary and benefits earned through the termination date.","CEO Amy Trombly signed the 8-K confirming the departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119531,"accession_number":"0001683168-25-007478","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Amy Trombly amends employment agreement; COO Bruce Thornton retires, position eliminated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Amy Trombly's base salary set at $475,000 per annum; target annual bonus of 50% of base salary.","CEO severance: termination without cause or for Good Reason: 1x base salary paid via payroll; COBRA up to 12 months.","CEO change-in-control severance: 2x base salary + 2x target bonus; COBRA up to 24 months.","COO Bruce Thornton to retire on Dec 2, 2025; position eliminated; severance $300,000 plus COBRA up to 12 months.","COO's time-based equity awards fully vest; performance-based awards remain per terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136098,"accession_number":"0001683168-25-007307","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals files updated investor presentation; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Furnished updated investor presentation dated September 29, 2025, under Item 8.01.","Presentation excerpt contains only legal disclaimers and forward-looking statements; no financial or operational updates visible.","No revenue, product, or guidance figures provided in the filing text or exhibit excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136097,"accession_number":"0001683168-25-007265","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sonoma Pharma enters $2.07M ATM stock offering with Ladenburg Thalmann","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At Market Issuance Sales Agreement with Ladenburg Thalmann for up to $2,070,463 of common stock.","Ladenburg receives 3% commission on gross proceeds; Company reimburses up to $40,000 in expenses.","Sales under existing S-3 effective Nov 20, 2023; prospectus supplement filed Sep 26, 2025.","Company not obligated to sell any shares; no assurance of price, amount, or timing of sales.","Agreement terminates upon sale of all shares or earlier per its terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136096,"accession_number":"0001683168-25-006580","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sonoma Pharmaceuticals shareholders elect director, approve executive compensation and auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Jay Birnbaum elected Class II director with 123,034 votes for, 19,478 withheld.","Non-binding advisory vote to approve named executive officer compensation passed 112,548 for, 26,360 against, 3,604 abstain.","Ratification of Frazier & Deeter as auditor for FY ending March 31, 2026 passed with 702,484 for, 13,569 against, 2,416 abstain.","Adjournment proposal passed with 576,908 for, 140,513 against, 1,048 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153146,"accession_number":"0001683168-25-002874","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals files updated investor presentation; no specific new data in excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed an updated investor presentation as of April 28, 2025, under Item 8.01.","The excerpt provided contains only legal disclaimers and forward-looking language; no operational or financial updates are visible.","No changes to strategy, guidance, or product pipeline can be extracted from the available text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153145,"accession_number":"0001683168-25-002294","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals posts updated investor presentation with no material new information","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed updated investor presentation as of April 7, 2025, under Item 8.01.","Presentation contains only standard disclaimers and forward-looking statements; no new financial or operational data disclosed.","No changes to guidance, product pipeline, revenue, or other key metrics were reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171927,"accession_number":"0001683168-25-001857","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sonoma expands Microcyn distribution deal with WellSpring to include additional products","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Amendment No. 1 dated March 21, 2025 adds new Microcyn-based products to existing Master Supply Agreement.","Distributor exclusivity rights broadened per revised Attachment A; original agreement dated Jan 29, 2025.","Upfront labeling fee per SKU required (amount redacted) upon initial purchase order for new products.","Initial term remains two years with three automatic one-year renewals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171926,"accession_number":"0001683168-25-000611","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sonoma inks exclusive US distribution deal with WellSpring for Microcyn products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive US distribution agreement with WellSpring Pharmaceutical, effective Jan 29, 2025.","Initial term of 2 years with three automatic one-year renewal periods.","WellSpring to distribute Microcyn-based products through defined channels; Sonoma retains all IP.","WellSpring must use commercially reasonable efforts and cannot sell competing hypochlorous acid products in those channels.","Pricing, minimum quantities, and forecasts are set in confidential attachments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171925,"accession_number":"0001683168-25-000076","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sonoma Pharma grants 7,500 options to directors and 10,000 RSUs to each top executive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-employee directors each received 7,500 options at $2.68, vesting over three years.","CEO Amy Trombly granted 10,000 RSUs; vesting at 6, 18, and 24 months.","CFO Jerry Dvonch and COO Bruce Thornton each granted 10,000 RSUs with same vesting schedule.","All awards vest upon change of control as part of annual equity grant program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188924,"accession_number":"0001683168-24-008332","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Sonoma Pharmaceuticals terminates exclusive supply agreement with EMC Pharma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EMC Pharma failed to meet minimum purchase quantities; 30-day cure period expired.","Termination effective November 21, 2024; no penalties incurred by Sonoma.","Sonoma resumes direct U.S. sales of Microcyn-based products: Acuicyn, Celacyn, Epicyn, Lasercyn, Levicyn.","Agreement had a five-year initial term; exclusive distribution rights now ended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188923,"accession_number":"0001683168-24-007283","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sonoma expands Medline distribution to Canada and OTC retail in US and Canada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to Distribution Agreement with Medline dated Oct 17, 2024 adds Canada and OTC wound care sales to retailers.","Original 5-year US distribution deal signed Aug 19, 2024; now covers both countries and OTC channel.","Updated investor presentation (Oct 22, 2024) highlights 20% YoY European revenue growth in Q1 FY2025 and gross margin improvement to 39%.","New FDA 510(k) clearance received Sep 2024 for OTC face/eyelid/eyelash indications and smaller product size.","Distribution expanded in Ukraine, South Korea, and EU through new partners in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205395,"accession_number":"0001683168-24-006556","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals files prospectus supplement for existing ATM equity offering with Maxim Group","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered Equity Distribution Agreement with Maxim Group on Dec 15, 2023, amended March 8, 2024.","Prospectus supplement filed Sept 20, 2024 under effective S-3 registration statement (File No. 333-275311).","Shares sold under ATM via Maxim as sales agent; no specific number or amount disclosed in filing.","Polsinelli PC opinion on validity of shares filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205394,"accession_number":"0001683168-24-006053","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["5.03","5.07","7.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals announces 1-for-20 reverse stock split effective Aug 29 to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares increased from 24M to 50M; reverse split ratio 1:20 effective Aug 29, 2024 at 5pm EDT.","Post-split common shares outstanding ~1M; trading begins on split-adjusted basis Aug 30, 2024.","Split intended to meet Nasdaq $1 minimum bid price requirement by Sept 16, 2024; no assurance of compliance.","Stockholders re-elected Philippe Weigerstorfer and Amy Trombly as Class I directors; reincorporation to Nevada not approved.","All proposals at annual meeting approved except reincorporation; auditor ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205393,"accession_number":"0001683168-24-005980","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals files prospectus supplement for existing at-the-market equity offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered into Equity Distribution Agreement with Maxim Group LLC on Dec 15, 2023, amended March 8, 2024.","Prospectus supplement filed Aug 23, 2024 for sales of common stock under effective S-3 registration statement.","Shares may be offered and sold through Maxim as sales agent or principal, at-the-market.","Legal opinion of Polsinelli PC regarding share validity filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205392,"accession_number":"0001683168-24-005938","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals enters 5-year distribution agreement with Medline for wound care products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Distribution agreement effective August 19, 2024, covers wound cleansers and other products in the United States.","Initial term of 5 years with automatic one-year renewal periods unless either party provides non-renewal notice.","Medline to submit orders via EDI; Supplier must maintain a specified fill rate and lead time with performance-related discounts.","Termination rights for material breach (30-day cure period) or bankruptcy; Medline can also terminate for quality or fill rate failures.","Agreement includes standard confidentiality, indemnification, and recall cooperation provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222304,"accession_number":"0001683168-24-004506","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals files prospectus supplement for ATM equity facility","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Filed a prospectus supplement on June 27, 2024 for at-the-market offering of common stock through Maxim Group LLC.","Agreement originally dated Dec 15, 2023, and amended March 8, 2024; no changes to terms disclosed.","Polsinelli PC legal opinion on share validity filed as Exhibit 5.1.","No sales amounts or proceeds reported; facility remains available for use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222303,"accession_number":"0001683168-24-002224","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals files updated investor presentation highlighting HOCl product portfolio and global reach","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation covers stabilized hypochlorous acid products for wound, eye, oral, nasal, and dermatological care.","Products sold in 55 countries directly or through distribution partners.","No new financial guidance, specific revenue figures, or material developments disclosed in the presentation.","Company continues to seek new distribution partners for global expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222302,"accession_number":"0001683168-24-002051","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals updates investor presentation; no material changes","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["HOCl product portfolio covers wound, eye, oral, nasal, dermatology, podiatry, and animal health","Products sold in 55 countries via direct sales and distribution partners","No new financial guidance or material business developments in the presentation"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241818,"accession_number":"0001683168-24-001635","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq grants Sonoma Pharmaceuticals 180-day extension to meet $1.00 bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received until September 16, 2024 to regain compliance with Nasdaq minimum $1.00 closing bid price rule.","Initial compliance deadline of March 20, 2024 was not met; deficiency first disclosed in September 2023.","If bid price closes at $1.00+ for 10 consecutive business days before Sept 16, Nasdaq will confirm compliance.","Failure to cure by Sept 16 could lead to delisting; company may appeal or consider reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241817,"accession_number":"0001683168-24-001399","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals increases ATM offering capacity by $785,679","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to Dec 2023 Equity Distribution Agreement with Maxim Group LLC allows sale of up to $785,679 in additional common shares.","Shares will be sold under existing effective S-3 registration statement (File No. 333-275311) and a prospectus supplement filed March 8, 2024.","No specific use of proceeds disclosed; prior ATM offerings typically used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241816,"accession_number":"0001683168-24-000168","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sonoma provides January 2024 investor presentation; no material new financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation reiterates stabilized HOCl platform for dermatology, wound, eye, nasal, oral, animal health.","Products sold in 55 countries directly or through distribution partners.","Company actively seeking additional distribution partners to expand global reach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241815,"accession_number":"0001683168-24-000150","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sonoma Pharma enters 2-year exclusive EU license for Avenova eye products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to use Avenova marks on Ocudox eye products in EU, effective Jan 5, 2024.","Initial 2-year term auto-renewing; royalty on Net Sales (percentage redacted) due quarterly.","Marketing through Sonoma's existing EU distribution network; NovaBay retains rights outside territories.","NovaBay represents it owns the marks, but applications in EU are still pending as previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259260,"accession_number":"0001683168-23-009150","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sonoma Pharmaceuticals grants 180,000 stock options to executive officers at $0.18 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Amy Trombly, interim CFO Jerry Dvonch, and COO Bruce Thornton each received 60,000 options.","Exercise price of $0.18 is based on December 29, 2023 closing price.","Options vest in three equal annual tranches; non-employee directors waived their grants.","All options fully vest upon a change of control.","Total options granted to executive officers: 180,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259259,"accession_number":"0001683168-23-008898","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals enters into ATM equity distribution agreement with Maxim Group for up to $392,077","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM facility allows Sonoma to sell up to $392,077 of common stock through Maxim Group.","Maxim receives 3% commission per sale plus expense reimbursement up to $20,000.","Sales under effective S-3 registration statement (333-275311) declared effective Nov 20, 2023.","Company not obligated to sell any shares; no assurance of price, timing, or amount.","Agreement terminates upon full sale of shares or earlier per its terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259258,"accession_number":"0001683168-23-007044","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals provides updated investor presentation; no material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Exhibit 99.1 contains an updated corporate presentation dated October 2023.","Presentation reiterates focus on stabilized hypochlorous acid products across multiple therapeutic areas.","Company states products sold directly or via partners in 55 countries.","No new financial guidance, product approvals, or strategic transactions disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259257,"accession_number":"0001683168-23-007057","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K/A","filed_at":"2023-10-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals files amended 8-K with updated investor presentation; no material new information","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Amended filing corrects item number from original 8-K dated October 11, 2023.","Investor presentation (October 2023) describes stabilized hypochlorous acid products for dermatology, wound care, etc.","Products are sold directly or via partners in 55 countries; company actively seeks distribution partners.","Presentation contains no financial results, guidance, or material operational updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276526,"accession_number":"0001683168-23-006809","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["3.01","5.07"],"status":"ready","headline":"Sonoma Pharma receives Nasdaq delisting notice for bid price non-compliance; say-on-pay vote fails","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sept 22, 2023 for failure to maintain $1 minimum bid price for 30 consecutive days.","Granted 180-day compliance period until March 20, 2024; needs $1 closing bid for 10 consecutive business days.","Annual meeting on Sept 28, 2023: non-binding advisory vote on executive compensation did NOT pass (560,065 for, 290,657 against, 8,188 abstain).","Stockholders ratified Frazier & Deeter as independent auditor for FY ending March 31, 2024 (2,560,351 for, 41,495 against, 3,765 abstain).","Jerry McLaughlin elected Class III director with 552,672 for, 306,238 withheld."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276525,"accession_number":"0001683168-23-004933","cik":1367083,"company_name":"Sonoma Pharmaceuticals, Inc.","ticker":"SNOA","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sonoma Pharmaceuticals appoints Controller and sets new interim CFO consulting terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Dal Poggetto appointed Controller effective July 17, 2023; annual salary $100,000, bonus up to 20%, option grant for 5,000 shares vesting over three years.","New consulting agreement with Jerome Dvonch Consulting, LLC at $20,000/month, effective August 15, 2023, with Dvonch continuing as interim CFO.","Dvonch's vested equity awards extended by one extra month per month of continued service, capped by current plan provisions.","Dal Poggetto will work part-time, reporting to interim CFO Dvonch; role is at-will with standard benefits and 3 weeks vacation.","No changes to other executive officers or board composition disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3855644.611111111,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}